Michael Tomsicek
Direktor/Vorstandsmitglied bei MILESTONE PHARMACEUTICALS INC.
Vermögen: 189 500 $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Kristina Masson | M | 44 | 6 Jahre | |
Peter Blume-Jensen | M | 62 | 6 Jahre | |
Thomas DesRosier | M | 69 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 11 Jahre |
Meredith Schaum | F | - |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 11 Jahre |
Joseph Oliveto | M | 56 | 7 Jahre | |
Robert Wills | M | 70 | 4 Jahre | |
Harold Edward Fleming | M | 61 | 3 Jahre | |
Derek DiRocco | M | 43 | 3 Jahre | |
Lukas Jeker | M | - |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | - |
John Greene | M | 58 | 5 Jahre | |
Katherine High | M | 72 | 5 Jahre | |
Lisa Giles | F | 65 | 4 Jahre | |
Richard Pasternak | M | 75 | 5 Jahre | |
Erick Gamelin | M | 67 | 3 Jahre | |
Howard J. Dreskin | M | - |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 17 Jahre |
Pamela S. Sears | M | - |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 22 Jahre |
Sharon Shacham | M | 53 | 4 Jahre | |
Debra Liebert | F | 67 | 9 Jahre | |
Doug Treco Treco | M | 66 | 4 Jahre | |
Karl Hsu | M | - | - | |
Jeffrey Blizard | M | 54 | 7 Jahre | |
Bruce Close | M | - | - | |
Thomas Fuchs | M | - |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | - |
Roshan Girglani | M | - | 2 Jahre | |
Kimberly Sheehan | F | - | 2 Jahre | |
Debbie K. Everidge | F | - | 3 Jahre | |
Anita Holz | F | - | 2 Jahre | |
David Bharucha | M | 62 | 2 Jahre | |
Adam Levy | M | - | 1 Jahre | |
Robert Perez | M | 59 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 11 Jahre |
Jean-Marie Cuillerot | M | - | - | |
Karen Mahoney | F | 80 | 7 Jahre | |
Amit Hasija | M | 51 | 5 Jahre | |
Mary Miller | F | 50 | - | |
Jeff Nelson | M | 42 | 4 Jahre | |
Rasmus Holm-Jorgensen | M | 53 | 2 Jahre | |
Alexander Mayweg | M | 49 |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | - |
Ivana Magovcevic-Liebisch | M | 55 | - | |
Charles Baum | M | 65 | 1 Jahre | |
Thomas Reps | M | - |
University of Wisconsin
| 39 Jahre |
Stephen Kennedy | M | 67 | 5 Jahre | |
Lorenz Muller | M | 60 | 7 Jahre | |
Guy Rousseau | M | - | 8 Jahre | |
Sherwood L. Gorbach | M | 89 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 19 Jahre |
Seth Fischer | M | 68 | 1 Jahre | |
Rajshree Kandadai | F | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Michael Chang | M | 73 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 15 Jahre |
Henry McKinnell | M | 81 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 2 Jahre |
Paul Truex | M | 55 | 10 Jahre | |
David McGirr | M | 69 | 12 Jahre | |
Maya K. Bittar | F | - |
University of Wisconsin
| 9 Jahre |
Donald A. Johnson | M | - |
University of Wisconsin
| 11 Jahre |
Azita Saleki-Gerhardt | M | 60 |
University of Wisconsin
| 8 Jahre |
Bart F. Reuter | M | - |
University of Wisconsin
| 8 Jahre |
Christopher D. van Gorder | M | 71 | 6 Jahre | |
Scott Ray Powell | M | - |
University of Wisconsin
| 7 Jahre |
Paul Stone | M | 60 |
University of Wisconsin
| 7 Jahre |
Tim L. Voigtman | M | - |
University of Wisconsin
| 8 Jahre |
Yu Neng Lim | M | 61 |
University of Wisconsin
| 5 Jahre |
Jun Ni | M | 61 |
University of Wisconsin
| 4 Jahre |
Laura Agran | F | - |
University of Wisconsin
| 5 Jahre |
Chantell Johnson | F | - |
University of Wisconsin
| 6 Jahre |
Chris Nisbet | M | - |
University of Wisconsin
| 9 Jahre |
Doug Giageos | M | - |
University of Wisconsin
| 7 Jahre |
Nancy Hutson | M | 74 | 7 Jahre | |
Timothy L. Maness | M | 63 | 1 Jahre | |
Mohammad Khalid Osama Asfour | M | 59 |
University of Wisconsin
| 6 Jahre |
Thomas Honggo Setjokusumo | M | 60 |
University of Wisconsin
| 3 Jahre |
Armand Ardika | M | 46 |
University of Wisconsin
| 6 Jahre |
Dan Nickow | M | - |
University of Wisconsin
| 5 Jahre |
Nilesh Kumar | M | 47 | 2 Jahre | |
Jonathan F. McAnulty | M | - |
University of Wisconsin
| 5 Jahre |
Kala Subramanian | M | 57 | - | |
Marco Boorsma | M | 49 | 2 Jahre | |
Louis E. Lataif | M | 84 | 10 Jahre | |
Thomas Woiwode | M | 52 | 5 Jahre | |
Paul Leff | M | - |
University of Wisconsin
| 5 Jahre |
Pablo Cagnoni | M | 60 | 4 Jahre | |
Joseph Chang | M | 71 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 15 Jahre |
Timothy Mattke | M | 48 |
University of Wisconsin
| 5 Jahre |
Jeannine M. Rivet | F | 76 | 6 Jahre | |
Henri A. Termeer | M | 78 | 30 Jahre | |
Lonnie Moulder | M | 66 | 5 Jahre | |
Jay Robert Sekelsky | M | 65 |
University of Wisconsin
| 6 Jahre |
Robert Zerbe | M | 73 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 4 Jahre |
Mike Reckmeyer | M | - |
University of Wisconsin
| 7 Jahre |
Jim Stephenson | M | - |
University of Wisconsin
| 6 Jahre |
Greg J. Schroeder | M | - |
University of Wisconsin
| 8 Jahre |
Kurt von Emster | M | 56 | 4 Jahre | |
Tom Cole | M | - |
University of Wisconsin
| - |
Vince Russo | M | - |
University of Wisconsin
| 6 Jahre |
Reik Watson Read | M | - |
University of Wisconsin
| 6 Jahre |
N. Coles | M | 63 | 2 Jahre | |
Jill Marie Grueninger | F | - |
University of Wisconsin
| 6 Jahre |
Anthony Altig | M | 68 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 6 Jahre |
Peter E. Grebow | M | 77 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 4 Jahre |
James Thalacker | M | - |
University of Wisconsin
| 8 Jahre |
Mark Auerbach | M | 85 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 8 Jahre |
Tirtha Chakraborty | M | 51 | 3 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 66 | 66,67% |
Kanada | 19 | 19,19% |
Schweiz | 14 | 14,14% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Michael Tomsicek
- Persönliches Netzwerk